Skip to main content
main-content
Erschienen in: Current Neurology and Neuroscience Reports 9/2019

01.09.2019 | Movement Disorders (T. Simuni, Section Editor)

Tardive Dyskinesia: Treatment Update

verfasst von: Divya Arya, Tarannum Khan, Adam J. Margolius, Hubert H. Fernandez

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Tardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics. It often distresses individuals, physically and emotionally and affects their quality of life. We evaluated peer-reviewed recently published articles with a goal of providing a critically appraised update on the latest advancements in this field.

Recent Findings

In 2017, FDA approved VMAT2 inhibitors, deutetrabenazine and valbenazine. They have demonstrated efficacy in several class 1 studies. Also there have been update in the evidence-based guidelines for treatment for tardive dyskinesia.

Summary

Various medication classes are being used for treatment of TD with VMAT2 inhibitors to be first FDA-approved medications. Their use should be tailored to the individual patient. Long-term studies will further guide us in how to optimize treatment, especially in the real-world setting. As clinicians, we need to take into consideration all aspects of symptomatology, etiology, potential side effects of the medications, to find the best possible “match” for our patients.
Literatur
1.
Zurück zum Zitat Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F, Kupfer D, editors. Psychopharmacology: the fourth generation of progress. New York: Raven press; 1995. p. 1485–96. Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F, Kupfer D, editors. Psychopharmacology: the fourth generation of progress. New York: Raven press; 1995. p. 1485–96.
2.
Zurück zum Zitat Sigwald J, Bottier D, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l’evolution prolongee secondaire a un traitement par les neuroleptiques. Rev Neurol ( Paris ). 1959;100:751–5. Sigwald J, Bottier D, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l’evolution prolongee secondaire a un traitement par les neuroleptiques. Rev Neurol ( Paris ). 1959;100:751–5.
4.
Zurück zum Zitat Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Ward. Neurology and Therapy Volume: 7 Issue 2 (2018) ISSN: 2193–8253 Online ISSN: 2193–6536 ane, 1995. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Ward. Neurology and Therapy Volume: 7 Issue 2 (2018) ISSN: 2193–8253 Online ISSN: 2193–6536 ane, 1995.
6.
Zurück zum Zitat Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74. PubMedPubMedCentral Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74. PubMedPubMedCentral
8.
Zurück zum Zitat Martins MR, Petronilho FC, Gomes KM, Dal-Pizzol F, Streck EL, Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox Res. 2008;13(1):63–9. PubMedCrossRef Martins MR, Petronilho FC, Gomes KM, Dal-Pizzol F, Streck EL, Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox Res. 2008;13(1):63–9. PubMedCrossRef
9.
Zurück zum Zitat Casey DE, Gerlach J, Magelund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37(12):1376–9. PubMedCrossRef Casey DE, Gerlach J, Magelund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37(12):1376–9. PubMedCrossRef
10.
Zurück zum Zitat Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–48 viii. PubMedPubMedCentralCrossRef Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–48 viii. PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardivedyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–7 Review. PubMedCrossRef Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardivedyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–7 Review. PubMedCrossRef
13.
Zurück zum Zitat Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(Suppl 4):12–9. PubMed Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(Suppl 4):12–9. PubMed
15.
Zurück zum Zitat Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull. 1995;31(2):259–64. PubMed Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull. 1995;31(2):259–64. PubMed
16.
Zurück zum Zitat Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry. 1994;28(2):328–30. PubMedCrossRef Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry. 1994;28(2):328–30. PubMedCrossRef
23.
25.
Zurück zum Zitat Tenback DE, Bakker PR, van Harten PN. Risk factors for tardive movement disorders in schizophrenia [in Dutch]. Tijdschr Psychiatr. 2015;57(2):120–4. PubMed Tenback DE, Bakker PR, van Harten PN. Risk factors for tardive movement disorders in schizophrenia [in Dutch]. Tijdschr Psychiatr. 2015;57(2):120–4. PubMed
27.
Zurück zum Zitat Guy W. ECDEU assessment manual of psychopharmacology Washington, DC: US department of health, Education and welfare. 1976. Guy W. ECDEU assessment manual of psychopharmacology Washington, DC: US department of health, Education and welfare. 1976.
28.
Zurück zum Zitat Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005;76(2–3):247–65 Epub 2005 Apr 18. Erratum in: Schizophr Res. 2006 Jul; 85(1–3):305. PubMedCrossRef Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005;76(2–3):247–65 Epub 2005 Apr 18. Erratum in: Schizophr Res. 2006 Jul; 85(1–3):305. PubMedCrossRef
29.
Zurück zum Zitat Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64(2):171–9. PubMedCrossRef Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64(2):171–9. PubMedCrossRef
30.
Zurück zum Zitat •• Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–9. https://​doi.​org/​10.​1212/​WNL.​0b013e31829d86b6​ Review. Erratum in: Neurology. 2013 Nov 26; 81(22):1968. This article tells about the level of efficacy of miscellaneous treatments for the TD. PubMedCrossRef •• Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–9. https://​doi.​org/​10.​1212/​WNL.​0b013e31829d86b6​ Review. Erratum in: Neurology. 2013 Nov 26; 81(22):1968. This article tells about the level of efficacy of miscellaneous treatments for the TD. PubMedCrossRef
31.
Zurück zum Zitat •• Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75. https://​doi.​org/​10.​1016/​j.​jns.​2018.​02.​010 Epub 2018 Feb 5. Review. Bhidayasiri R et al in 2018 published the algorithms that can help physicians to go step by step to figure about the treatment. PubMedCrossRef •• Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75. https://​doi.​org/​10.​1016/​j.​jns.​2018.​02.​010 Epub 2018 Feb 5. Review. Bhidayasiri R et al in 2018 published the algorithms that can help physicians to go step by step to figure about the treatment. PubMedCrossRef
32.
Zurück zum Zitat Semin Neurol. 2007 Apr; 27(2):159-69. Tardive dyskinesia. Soares-Weiser K 1, Fernandez HH. Semin Neurol. 2007 Apr; 27(2):159-69. Tardive dyskinesia. Soares-Weiser K 1, Fernandez HH.
34.
Zurück zum Zitat Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;21(Pt11):2053–66. CrossRef Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;21(Pt11):2053–66. CrossRef
37.
Zurück zum Zitat Margolese HC, Chouinard G, Kolivakis TT, Beau-clair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatr. 2005;50(11):703–14. CrossRef Margolese HC, Chouinard G, Kolivakis TT, Beau-clair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatr. 2005;50(11):703–14. CrossRef
39.
Zurück zum Zitat Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56 Review. PubMed Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56 Review. PubMed
41.
Zurück zum Zitat • Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychi-atry. 2017;174(5):476–84. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. CrossRef • Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychi-atry. 2017;174(5):476–84. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. CrossRef
42.
Zurück zum Zitat • Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia. J Clin Psy-chiatry. 2017;78(9):1344–50. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. CrossRef • Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia. J Clin Psy-chiatry. 2017;78(9):1344–50. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. CrossRef
43.
Zurück zum Zitat • Ingrezza [package insert]. San Diego: Neurocrine Biosciences; 2017. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia. • Ingrezza [package insert]. San Diego: Neurocrine Biosciences; 2017. This reference gives us insight about use of new VMAT 2 inhibitor—valbenazine—approved by FDA for the treatment of tardive dyskinesia.
44.
Zurück zum Zitat • Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoja¨rvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedCrossRef • Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoja¨rvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedCrossRef
45.
Zurück zum Zitat • Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21):2003–10. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedPubMedCentralCrossRef • Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21):2003–10. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat • AUSTEDO [package insert]. North Wales: Auspex Pharmaceuticals; 2017. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. • AUSTEDO [package insert]. North Wales: Auspex Pharmaceuticals; 2017. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia.
47.
Zurück zum Zitat • Fernandez, et al. Long-term safety and efficacy of deutetrabenazine for treatment of tardive dyskinesia. JNNP. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. • Fernandez, et al. Long-term safety and efficacy of deutetrabenazine for treatment of tardive dyskinesia. JNNP. This reference gives us insight about use of new VMAT 2 inhibitor—deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia.
48.
Zurück zum Zitat • Solmi M, Pigato, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–38. This reference gives us insight about use of new VMAT 2 inhibitors—valbenazine and deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedPubMedCentralCrossRef • Solmi M, Pigato, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–38. This reference gives us insight about use of new VMAT 2 inhibitors—valbenazine and deutetrabenazine—approved by FDA for the treatment of tardive dyskinesia. PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93. PubMedCrossRef Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93. PubMedCrossRef
53.
Zurück zum Zitat Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51. PubMedCrossRef Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51. PubMedCrossRef
54.
Zurück zum Zitat Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology. 1978;56(2):145–51. PubMedCrossRef Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology. 1978;56(2):145–51. PubMedCrossRef
55.
Zurück zum Zitat Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–5. PubMedCrossRef Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–5. PubMedCrossRef
56.
Zurück zum Zitat Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:CD000204. PubMed Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:CD000204. PubMed
58.
Zurück zum Zitat Van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276–7. PubMedCrossRef Van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276–7. PubMedCrossRef
59.
Zurück zum Zitat Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, Mosheva T, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15(2):352–5. PubMedCrossRef Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, Mosheva T, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15(2):352–5. PubMedCrossRef
60.
Zurück zum Zitat Kañovský P, Streitová H, Bares M, Hortová H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of long-lasting effect. Mov Disord. 1999;14(5):886–8. PubMedCrossRef Kañovský P, Streitová H, Bares M, Hortová H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of long-lasting effect. Mov Disord. 1999;14(5):886–8. PubMedCrossRef
Metadaten
Titel
Tardive Dyskinesia: Treatment Update
verfasst von
Divya Arya
Tarannum Khan
Adam J. Margolius
Hubert H. Fernandez
Publikationsdatum
01.09.2019
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 9/2019
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-019-0976-1

Weitere Artikel der Ausgabe 9/2019

Current Neurology and Neuroscience Reports 9/2019 Zur Ausgabe

Headache (R.B. Halker Singh, Section Editor)

Updates in the Diagnosis and Management of Giant Cell Arteritis

Neurotrauma (D. Sandsmark, Section Editor)

Semiology and Mechanisms of Near-Death Experiences

Stroke (H.C. Diener, Section Editor)

Multimodal CT in Acute Stroke

Neurotrauma (D. Sandsmark, Section Editor)

Modern Medical Management of Spinal Cord Injury

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Neurologie und bleiben Sie gut informiert – ganz bequem per eMail.